Research memoThe Cooper Companies, Inc. (COO) · NASDAQMemo of October 24, 2026By Olivier Lachance

Cooper earnings

MyStockButler's October 2026 analysis: Cooper's next results are expected on December 3, 2026. Watch whether lens orders recover as inventory normalizes.

December 3, 2026
Next results
1,066.2
Revenue, quarter to Jul 2026 (US$ millions)
2.24
EPS, diluted, quarter to Jul 2026
Read the full Cooper memoYour first S&P 500 report is free · no card
Every number traced to Cooper's filings8 chapters · 22,294 words206 sources cited

What has Cooper guided for FY2026?

Management guides CooperVision organic revenue growth of -2% to 0%. The guidance covers the quarter to October 2026. CooperSurgical is guided to 4% to 6%. FY2026 guidance calls for 2% to 3% organic revenue growth and $4.51–$4.55 non-GAAP diluted EPS. The FY2026–2028 free-cash-flow objective exceeds $2,200.0 million. MiSight growth is expected at 20.0% in FY2026.

Cooper (COO): Revenue by quarter (US$ millions): Oct 2024 1,018.4, Jul 2026 1,066.2; EPS $2.24
Guidance in forceUS$ millions
The period guidedLowHighThe date it was given
total revenue (Year to Oct 2026)Year to Oct 20264,229.04,252.0Sep 9, 2026
total revenue, organic growth (%) (Year to Oct 2026)Year to Oct 20262.0%3.0%Sep 9, 2026
non-GAAP diluted EPS (Year to Oct 2026)Year to Oct 20264.514.55Sep 9, 2026
long-term free cash flow objective (Fiscal 2026 through 2028)Fiscal 2026 through 20282,200.0Sep 9, 2026
MiSight growth (%) (Year to Oct 2026)Year to Oct 202620.0%20.0%Sep 9, 2026

What this means. The long-term free cash flow objective is a minimum of more than 2.2 billion United States dollars, not a range with a missing upper limit.

Has Cooper kept its past promises?

Guidance is another test. Cooper’s March 2026 presentation projected adjusted annual earnings of US$4.58–US$4.66 per share; its September forecast was US$4.51–US$4.55. Management also reaffirmed a free-cash-flow objective exceeding $2.2 billion for fiscal 2026–2028. Guidance is a forecast, while free cash flow is delivered cash, so the objective remains unproved. JANA’s call for revised compensation metrics reflects that gap: shareholders want rewards tied not only to forecasts, but to cash and returns.

What do Cooper's last eight quarters show?

The last eight quartersUS$ millions
Jul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024
Revenue1,066.21,081.51,024.11,065.21,060.31,002.3964.71,018.4
Gross margin66.8%68.0%67.9%61.1%65.3%67.8%68.4%66.5%
Operating income222.0-31.0212.8140.4175.7184.8182.0198.4
Net income432.8-77.9130.884.698.387.7104.3117.5
EPS, diluted2.24-0.400.660.430.490.440.520.58
= Free cash flow273.096.4158.7149.9164.518.1101.2128.1

What this means. Net income in July 2026 is unusually high because the company recorded a one-time tax benefit of 307.2 million dollars.

What should you watch in Cooper's next results?

The practical takeaway is demanding but clear: Cooper must turn its product investment into lens growth while funding legal obligations and debt without weakening execution.

From the full memo · 1. The business

CooperCompanies is a medical-products company with two engines: contact lenses and products and services for fertility and women’s health. A dollar reaches it through retailers, clinics, hospitals and distributors, then leaves through manufacturing, care delivery, selling, research and investment.

Continue reading, free
Your first S&P 500 report is free · no card

Where these numbers come from

More on Cooper

Cooper stock forecastAuf Deutsch

Its rivals

Johnson & Johnson (JNJ)

Browse

All stocksS&P 500 companiesCompanies C
The full Cooper memoYour first S&P 500 report is free
Read it